I don't know that ignoring MDV is the best plan. H

I don't know that ignoring MDV is the best plan. His experience is likely to make him less head over heals for Cytodyn than I am, but that does not mean he is wrong to address the other therapeutics in the clinical space and market place.

Many (not accusing you or anyone particularly) are concerned about big pharmaceuticals manipulation of the regulatory process. I am more concerned about true competitors.

I have no idea how long it takes to develop a new mAb and whether Cytodyns patents are solely for the structure or Leronlimab, or the approach of the therapy itself.

I believe Dr. Pourhassan stated that the patents on Leronlimab are good for 12 years after first approval, but if the company does not get large fast or partner with a BP to be its muscle, others could bully there way. These are the concerns that bother me more than whether a poster here has another agenda. The future of this company and our investments are highly unlikely to be determined by our actions here.